PubMed

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia.

Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ.

Nat Clin Pract Cardiovasc Med. 2008 Aug;5(8):497-505. Epub 2008 May 27.PMID: 18506154 [PubMed - indexed for MEDLINE]Related articles

Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.

Schwartz GG, Olsson AG, Szarek M, Sasiela WJ.

Diabetes Care. 2005 Oct;28(10):2508-13.PMID: 16186288 [PubMed - indexed for MEDLINE]Related articlesFree article

An association study of 43 SNPs in 16 candidate genes with atorvastatin response.

Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, Milad MA, Sasiela WJ.

Pharmacogenomics J. 2005;5(6):352-8.PMID: 16103896 [PubMed - indexed for MEDLINE]Related articles

High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.

Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A.

Eur Heart J. 2005 May;26(9):890-6. Epub 2005 Mar 11.PMID: 15764620 [PubMed - indexed for MEDLINE]Related articlesFree article

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.

Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators.

N Engl J Med. 2005 Jan 6;352(1):29-38.PMID: 15635110 [PubMed - indexed for MEDLINE]Related articlesFree article

High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.

Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.

Circulation. 2004 Sep 14;110(11):1406-12. Epub 2004 Sep 7.PMID: 15353498 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.

Circulation. 2004 Jul 27;110(4):386-91. Epub 2004 Jul 19.PMID: 15262833 [PubMed - indexed for MEDLINE]Related articlesFree article

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators.

Circulation. 2003 Sep 30;108(13):1560-6. Epub 2003 Sep 15.PMID: 12975259 [PubMed - indexed for MEDLINE]Related articlesFree article

Cellular models of atherosclerosis in the young.

Fowler SD, Gasque-Carter PD, Pattillo-Adkisson E, Sasiela WJ, Xenachis DN.

Ann N Y Acad Sci. 1991;623:60-9. Review.PMID: 2042876 [PubMed - indexed for MEDLINE]Related articles